Antipsychotic Prescription in Black and White Patients with First Psychotic Episode – A Study of Hospitalized Patients in Lisbon

A 30-year-old man with no significant previous or family psychiatric history became severely anxious about his health after a positive COVID-19 test. Physical symptoms of COVID-19 were mild, with no evidence of hypoxia or pneumonia, throughout his illness. He was admitted to a quarantine facility. He remained highly anxious, and 1 week later, he developed paranoid delusions and auditory hallucinations (his first psychotic episode). He was treated with lorazepam 1 mg four times a day, mirtazapine 30 mg nocte and risperidone 1 mg two times a day. His psychotic symptoms lasted 1 week. He stopped psychiatric medication after 4 weeks and had remained well when reviewed 3 months later. A Diagnostic and Statistical Manual of Mental Disorders fifth edition diagnosis of brief psychotic disorder with marked stressor (brief reactive psychosis) was made. Anxiety about his health and social isolation appeared the main aetiological factors but an inflammatory component cannot be excluded. The case highlights that first episode psychosis can be associated with mild COVID-19.

Download Full-text

Risperidone was effective for a first psychotic episode

Evidence-Based Mental Health ◽

10.1136/ebmh.3.3.77 ◽

2000 ◽

Vol 3 (3) ◽

pp. 77-77

Author(s):

A. McIntosh

Keyword(s):

Psychotic Episode ◽

First Psychotic Episode

Download Full-text

Family psycho-education in early onset psychosis: Effects on relapse and on the use of clinical services after the first psychotic episode (Results derived from the PIENSA program)

Neuropsychiatrie de l Enfance et de l Adolescence ◽

10.1016/j.neurenf.2012.04.785 ◽

2012 ◽

Vol 60 (5) ◽

pp. S284 ◽

Cited By ~ 1

Author(s):

M. Rapado-Castro ◽

A. Calvo ◽

C. Moreno ◽

T. Sánchez-Gutiérrez ◽

G. Chiclana ◽

...

Keyword(s):

Early Onset ◽

Psychotic Episode ◽

Clinical Services ◽

First Psychotic Episode ◽

Early Onset Psychosis

Download Full-text

Multi-ethnic Investigation of Risk and Immune Determinants of COVID-19 Outcomes

10.1101/2021.10.29.21265687 ◽

2021 ◽

Author(s):

Tomi Jun ◽

Divij Mathew ◽

Navya Sharma ◽

Sharon Nirenberg ◽

Hsin-Hui Huang ◽

...

Keyword(s):

Significant Interaction ◽

Interleukin 1 ◽

Black Population ◽

P Value ◽

Interleukin 1 Beta ◽

Black And White ◽

Race Ethnicity ◽

Study Setting ◽

Hispanic White ◽

White Patients

Objectives: To compare risk factors for COVID-19 mortality among hospitalized Hispanic, Non-Hispanic Black, and White patients. Design: Retrospecitve cohort study Setting: Five hosptials within a single academic health system Participants: 3,086 adult patients with self-reported race/ethnicity information presenting to the emergency department and hospitalized with COVID-19 up to April 13, 2020. Main outcome measures: In-hospital mortality Results: While older age (multivariable OR 1.06, 95% CI 1.05-1.07) and baseline hypoxia (multivariable OR 2.71, 95% CI 2.17-3.36) were associated with increased mortality overall and across all races/ethnicities, Non-Hispanic Black (median age 67, IQR 58-76) and Hispanic (median age 63, IQR 50-74) patients were younger and had different comorbidity profiles compared to Non-Hispanic White patients (median age 73, IQR 62-84; p<0.05 for both comparisons). Among inflammatory markers associated with COVID-19 mortality, there was a significant interaction between the Non-Hispanic Black population and interleukin-1-beta (interaction p-value 0.04). Conclusions: This analysis of a multi-ethnic cohort highlights the need for inclusion and consideration of diverse popualtions in ongoing COVID-19 trials targeting inflammatory cytokines.

Download Full-text